ClinicalTrials.gg
CompletedNCT07844213Updated Sep 28, 2026

Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone"

An interventional study of Control group (ambrisentan plus tadalafil or macitentan plus tadalafil) and Treatment group (ambrisentan plus tadalafil plus treprostinil or macitentan plus tadalafil plus treprostinil) in Congenital Heart Disease, Pulmonary Hypertension, sponsored by China National Center for Cardiovascular Diseases. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Aug 2022, registered Aug 2026).
Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Heart Defects, Congenital by China National Center for Cardiovascular Diseases — 5 open to participants now, 6 under way, none of them phase 3. Heart Defects, Congenital · China National Center for Cardiovascular Diseases.

Started
2022
with 5 others
No phase
2 of 10
none open now
Registered
10th of 10
by date

Among the 10 studies in Heart Defects, Congenital by China National Center for Cardiovascular Diseases, this one is one of 6 that started in 2022, is one of 2 with no phase, and was the 10th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

5 of the 10 studies in Heart Defects, Congenital by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Heart Defects, Congenital by China National Center for Cardiovascular Diseases, or all of them as a file.
02

Study summary

The purpose of this study is to observe the efficacy of early application of triple targeted drug therapy, including trilostane, in patients with congenital heart disease who are in the "gray zone" of preoperative evaluation, have surgical repair indications after evaluation, and have undergone defect repair.

Read the detailed description

This study is a prospective randomized controlled study. Including congenital heart disease combined with pulmonary hypertension, the hemodynamics in the right heart catheter before surgery conform to the "gray zone standard" (PVRi: 6-8 Wood * m2) in the 2018 Cologne Consensus.PVR/SVR 0.3-05), acute vascular reaction test met the positive standard (PVRi: \< 6 Wood*m 2, PVR/SVR \< 0.3), and CHD patients (including VSD, PDA, ASD) who underwent surgical repair, patients were randomly assigned to different treatment groups, The specific grouping is as follows: 1) 15 patients in the standard dual therapy group received dual therapy for 12 months, consisting of a phosphodiesterase type 5 inhibitor (tadalafil 20 mg qd or sildenafil 20\~25 mg tid) combined with a phosphodiesterase 5 receptor antagonist (amlodipine 5 mg qd or macitentan 10 mg qd). 2) 15 patients in the early triple therapy group received the combination of a phosphodiesterase type 5 inhibitor (tadalafil 20 mg qd or sildenafil 20\~25 mg tid), a phosphodiesterase-5 receptor antagonist (amlodipine 5 mg qd or maropitant 10 mg qd), and treprostinil. The dosage of pralatrexate needs to be titrated gradually, starting from 1.25 ng/min/kg, and titrated gradually to the patient's maximum tolerated dose (guideline dose of 15-20 ng/min/kg), and the duration of triple targeted drug therapy is at least 6 months. After 6 months, it can be adjusted to the standard dual therapy group to 12 months. Observation indexes The main observation indices are as follows:(1) Pulmonary vascular resistance measured by right heart catheterization one year after surgical repair and closure of defects. Secondary observation indicators: (1) Right atrial pressure, pulmonary artery pressure, PVR/SVR, cardiac index, mixed blood oxygen saturation, and systemic arterial blood oxygen saturation measured in right heart catheterization 12 months after surgery. (2) NT-proBNP level (3) 6-minute walk distance (4) WHO functional class (5) SF-36 self-assessment quality of life score (6) rehospitalization due to worsening heart failure, atrial septal defect shunt, lung transplant or heart-lung transplant, and other adverse events; (7) Drug-related adverse reaction events, including but not limited to hypotension, headache, muscle pain, injection site pain, injection site infection, bleeding, etc.

03

Conditions studied

  • Congenital Heart Disease, Pulmonary Hypertension

Keywords

  • Pulmonary hypertension
  • Congenital heart disease
  • Surgical repair
  • Targeted drug therapy
  • Prognosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 to 65
  • Patients with congenital heart disease and pulmonary hypertension with clear diagnosis
  • Pulmonary vascular resistance index (PVR) in hemodynamics of right heart catheterization before surgical repair: hemodynamics of right heartcatheterization before surgery conforms to "gray zone standard" (PVR: 4-8 Wood* m2, QP/QS > 1.5), acute vascular reaction test meets the positive standard (PVR: \< 4 Wood* m2)
  • Successfully performed surgical repair of congenital heart disease to close the defect
  • Sign form

Exclusion criteria

Exclusion Criteria:

  • Other causes of PAH include pulmonary hypertension associated with left heart disease (valve disease)
  • Other types of CHD-PAH, including Eisenmenger syndrome, PAH with small defects, etc.
  • After evaluating the acute pulmonary vasodilation test by right heart catheterization, the result shows that the surgical prognosis is poor, and those who are not suitable for surgical treatment should not undergo surgical treatment.
  • There are other surgical , including severe systemic diseases, severe mental disorders, severe cognitive dysfunction, and physical conditions that cannot tolerate surgery.
  • Cannot provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Dual therapy group

    Ambrisentan 10mg qd or Macitentan 10mg qd combined with Tadalafil 20-40mg qd

    Drug: Control group (ambrisentan plus tadalafil or macitentan plus tadalafil)

  • Experimental
    Early triple therapy group

    Ambrisentan 10mg qd or Macitentan 10mg qd combined with Tadalafil 20-40mg qd and Treprostinil

    Drug: Treatment group (ambrisentan plus tadalafil plus treprostinil or macitentan plus tadalafil plus treprostinil)

Interventions

  • DrugControl group (ambrisentan plus tadalafil or macitentan plus tadalafil)

    The control group received dual drug therapy: endothelin receptor antagonists (Ambrisentan 10mg qd, or Macitentan 10mg qd) combined with phosphodiesterase type 5 inhibitors (Tadalafil 20-40mg qd).

  • DrugTreatment group (ambrisentan plus tadalafil plus treprostinil or macitentan plus tadalafil plus treprostinil)

    The treatment group received early triple therapy: endothelin receptor antagonist (Ambrisentan 10 mg qd or Macitentan 10 mg qd), a phosphodiesterase type 5 inhibitor ( Tadalafil 20-40 mg qd), and treprostinil. The Treprostinil dose was titrated gradually, starting at 1.25 ng/min/kg and escalated to the patient's maximum tolerated dose (target dose range: 15-20 ng/min/kg).

06

What researchers measure

Primary outcomes

  1. Pulmonary vascular resistance

    Pulmonary vascular resistance measured by right heart catheterization

    Time frame: 12 months after surgical closure of the defect

Secondary outcomes

  1. Right atrial pressure

    The right atrial pressure was measured by the right heart catheterization

    Time frame: 12 months after surgery

  2. Pulmonary artery pressure

    Pulmonary artery pressure measured by the right heart catheterization

    Time frame: 12 months after surgical closure of the defect

  3. Ratio of pulmonary vascular resistance to systemic vascular resistance

    Pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR) were calculated from hemodynamic parameters obtained during right heart catheterization (RHC). PVR was calculated as (mean pulmonary artery pressure - pulmonary artery wedge pressure) divided by cardiac output. SVR was calculated as 80 × (mean arterial pressure - right atrial pressure) divided by cardiac output.

    Time frame: 12 months after surgical closure of the defect

  4. Cardiac index

    Cardiac index was calculated as cardiac output divided by body surface area. Cardiac output was measured during right heart catheterization.

    Time frame: 12 months after surgical closure of the defect

  5. Mixed venous oxygen saturation

    Mixed venous oxygen saturation was sampled and measured from the main pulmonary artery during right heart catheterization.

    Time frame: 12 months after surgical closure of the defect

  6. Systemic arterial blood oxygen saturation

    Systemic arterial blood oxygen saturation was determined from arterial blood samples obtained during right heart catheterization.

    Time frame: 12 months after surgical closure of the defect

  7. NT-proBNP

    Laboratory examination

    Time frame: 12 months after surgery

  8. 6 minutes walking distance

    On a flat, hard surface, the maximum distance walked by the subject at their own pace in 6 minutes

    Time frame: 12 months after surgery

  9. WHO heart function grading

    The standard set by the World Health Organization to assess the functional status of patients with heart disease: Grade I: No limitation in physical activity, no symptoms in daily activities Grade II: Mild limitation of activity, nothing happens when resting, but there will be shortness of breath and fatigue during daily activities. Level III: Activities are significantly limited, there is no problem when resting, but symptoms will be triggered by slight activities (below daily intensity). Grade IV: The most severe, symptoms are present at rest and worsen with any activity, and there may be signs of right heart failure.

    Time frame: 12 months after surgery

  10. The MOS 36-Item Short Form Health Survey (SF-36)

    The MOS 36-Item Short Form Health Survey (SF-36) was used to assess health-related quality of life. Each of its eight domains, as well as the physical component summary (PCS) and mental component summary (MCS), ranges from 0 to 100, with higher scores indicating better health status.

    Time frame: 12 months after surgery

  11. All kinds of adverse events

    Rehospitalization due to worsening heart failure, ventricular septal defect repair, lung transplantation or heart-lung transplantation, and other adverse events

    Time frame: 12 months after surgery

  12. Adverse drug reaction events

    Not limited to low blood pressure, headache, muscle soreness, injection site pain,Injection site infection, bleeding, etc.

    Time frame: 12 months after surgery

07

Study locations

1 site
  • Fuwai Hospital, National Center for Cardiovascular Diseases
    Beijing, 100037, China
08

References and documents

Publications

  • Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, Lung B, Kluin J, Lang IM, Meijboom F, Moons P, Mulder BJM, Oechslin E, Roos-Hesselink JW, Schwerzmann M, Sondergaard L, Zeppenfeld K; ESC Scientific Document Group. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021 Feb 11;42(6):563-645. doi: 10.1093/eurheartj/ehaa554. No abstract available. PubMed 32860028 ↗
  • Skoro-Sajer N, Gerges C, Balint OH, Kohalmi D, Kaldararova M, Simkova I, Jakowitsch J, Gabriel H, Baumgartner H, Gerges M, Sadushi-Kolici R, Celermajer DS, Lang IM. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension. Heart. 2018 Jul;104(14):1195-1199. doi: 10.1136/heartjnl-2017-312143. Epub 2018 Feb 7. PubMed 29436381 ↗
  • Thomas IC, Glassner-Kolmin C, Gomberg-Maitland M. Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease. Int J Cardiol. 2013 Oct 9;168(4):4117-21. doi: 10.1016/j.ijcard.2013.07.072. Epub 2013 Jul 25. PubMed 23890862 ↗
  • Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999 Apr 13;99(14):1858-65. doi: 10.1161/01.cir.99.14.1858. PubMed 10199883 ↗
  • Kozlik-Feldmann R, Hansmann G, Bonnet D, Schranz D, Apitz C, Michel-Behnke I. Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016 May;102 Suppl 2:ii42-8. doi: 10.1136/heartjnl-2015-308378. PubMed 27053697 ↗
  • Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P, Landzberg MJ, Saidi A, Valente AM, Van Hare GF. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e637-e697. doi: 10.1161/CIR.0000000000000602. No abstract available. PubMed 30586768 ↗

Individual participant data

Plan to share: No — Ethically, raw data contains sensitive personal information, and initial informed consent is often not authorized for external sharing, which may infringe on privacy and violate the trust of participants. From a legal perspective, strict compliance with relevant data protection regulations is required, and there are compliance risks and contractual constraints when transferring data across borders or to third parties. In practice, the establishment of a secure sharing platform is costly, and the degree of data standardization is inconsistent, which may lead to misunderstandings or misuses and affect the credibility of research.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jul 2025, 35 months.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 35 months is close to that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2026
First posted
Sep 28, 2026
StartActual
Aug 25, 2022
Primary completionActual
Jul 30, 2025
CompletionActual
Aug 31, 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844213
Responsible party
Yan Wu (clinical professor, China National Center for Cardiovascular Diseases) — Principal investigator
First posted
Sep 28, 2026
Start date
Aug 25, 2022
Primary completion
Jul 30, 2025
Completion
Aug 31, 2025
Last update
Sep 28, 2026

Study contacts

Wu Yan
study director · Fuwai Hospital, National Center for Cardiovascular Diseases

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion